CagriSema is a research combination of the amylin analogue cagrilintide (5mg) and the GLP-1 analogue semaglutide (5mg). The pairing is studied in metabolic and satiety-signalling research to explore complementary receptor pathways in laboratory models.
Supplied as a lyophilised powder, batch-identified and cross-referenced to a third-party HPLC Certificate of Analysis (COA). In keeping with the GenoPept standard — analytical purity over presentation — it ships in clinical packaging with discreet, tracked UK dispatch.
Research use only. Intended strictly for in-vitro laboratory and scientific research. Not for human or veterinary use.



Reviews
There are no reviews yet.